PNEUMOTACTIX, LLC

Athens, GA · Biotech · Private

Pneumozyme (Pn3Pase), an enzyme that degrades the polysaccharide capsule of Streptococcus pneumoniae serotype 3 to enhance immune clearance

pneumotactix.com →
Grants
$898K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection$598,900
Federal grantDepartment of Health and Human Services · Phase I · Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection$299,450
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2062Synthetic Biodesign, LLC——
2063Silverpeutics Inc.—$12M
2064General Probiotics Inc——
2065PNEUMOTACTIX, LLC——
2066VIRVIO, INC.——
2067Bespoke, Inc.—$14M
2068D BioTherapeutics, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.